Harrow Inc (HROW)

$45.43 -2.30 (-4.82%)
Market Cap 1.77B
Revenue (ttm) 199.61M
Net Income (ttm) -17.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 94.23
Profit Margin -8.76%
Debt to Equity Ratio 0.78
Volume 1,235,300
Avg Vol 656,714
Day's Range N/A - N/A
Shares Out 37.00M
Stochastic %K 8%
Beta 0.27
Analysts Strong Sell
Price Target $67.91

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract sur...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
Night_Owl_Biotech
Night_Owl_Biotech Oct. 4 at 10:21 PM
The attachment compares the projected revenue & EPS multiples of $LGND v. 3 peers $RPRX $XNCR $XOMA that also invest in biopharma royalties. LGND appears to be an amazing company with a great future. We are not bashing LGND. However, simple analytics suggest LGND, up ~80%+ since June 2025, is now over-priced primarily because they trade @ multiples 2X higher than these 3 peers. Of course we could be wrong. This is not investment advice. Shorting a stock like LGND is extremely risky because, in theory, losses are infinite. History suggests LGND might retract after reporting Q3 2025 earnings as valuation opportunity are reset (the $HROW phenomenon in May 2023...but HROW recovered & then some later). LGND also holds equity investments where valuation gains may not manifest in traditional revenues & earnings forecasts. Again, this is not investment advice. Comments? Pushback? Are these 3 not peers?
0 · Reply
Finnish_boy
Finnish_boy Oct. 4 at 9:37 PM
$HROW I will be quiet until next friday. Lets see if MVI posts BBG data. Buy all the bigger dips. Very tasty IPA ⬇️
0 · Reply
Finnish_boy
Finnish_boy Oct. 4 at 11:19 AM
$HROW
1 · Reply
Finnish_boy
Finnish_boy Oct. 4 at 9:38 AM
$HROW OSRX should have respected the rules. Think first before acting. Now the court did what they had to: https://youtube.com/shorts/7cuKeZMOCN4?si=jrtSEeRuo9yGcb8m
0 · Reply
Finnish_boy
Finnish_boy Oct. 4 at 8:52 AM
$HROW What you think will happen? OSRX will give up and pay what they can. Or they complain and delay the payments for 1-2 years and meanwhile they gather all the money to own pockets and find new jobs. OSRX will lose 100% sure anyways. What you think? Give up or delay?
2 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 8:30 AM
$HROW: Unusual Options Activity Alerted CALL flow observed 90x contracts at Strike price of $49 Exp on 11/21/2025 with Premium of $50K and showing NEUTRAL Sentiment
0 · Reply
MrMoneyBags4
MrMoneyBags4 Oct. 4 at 6:42 AM
$HROW Charts still look good. - Monthly: Structural uptrend intact. - Weekly: Still bullish — pullback within trend. - Daily: Short-term consolidation (typical after a run).
1 · Reply
Fullback
Fullback Oct. 3 at 10:47 PM
$HROW I didn't see this to just now, but maybe this might have been a driver for SP today? https://x.com/RevShark/status/1974117881563451702
2 · Reply
Finnish_boy
Finnish_boy Oct. 3 at 9:42 PM
$HROW https://www.vitallaw.com/news/trademark-s-d-cal-remittitur-granted-in-eye-medication-infringement-dispute/ipm0135d19d4ebb854eb38fd87fe0369f6e15?refURL=https%3A%2F%2Fwww.google.com%2F#.
1 · Reply
Finnish_boy
Finnish_boy Oct. 3 at 9:41 PM
$HROW
0 · Reply
Latest News on HROW
Harrow, Inc. (HROW) Analyst/Investor Day Transcript

Sep 27, 2025, 12:27 AM EDT - 7 days ago

Harrow, Inc. (HROW) Analyst/Investor Day Transcript

Harrow to Acquire Melt Pharmaceuticals

Sep 26, 2025, 7:00 AM EDT - 8 days ago

Harrow to Acquire Melt Pharmaceuticals

Harrow Launches Harrow Access for All (HAFA)

Sep 25, 2025, 4:05 PM EDT - 9 days ago

Harrow Launches Harrow Access for All (HAFA)

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 15, 2025, 7:00 AM EDT - 19 days ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Harrow: Buy A Blend Of Value And Growth

Sep 12, 2025, 10:57 AM EDT - 22 days ago

Harrow: Buy A Blend Of Value And Growth

Harrow: A Classical GARP Stock

Sep 9, 2025, 1:11 PM EDT - 25 days ago

Harrow: A Classical GARP Stock

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Sep 8, 2025, 5:57 PM EDT - 26 days ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Sep 8, 2025, 8:00 AM EDT - 26 days ago

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Harrow's Ambitious Guidance Puts It In The Proving Ground

Aug 14, 2025, 11:09 PM EDT - 7 weeks ago

Harrow's Ambitious Guidance Puts It In The Proving Ground

Harrow: Exciting Times In Store

Aug 13, 2025, 5:39 PM EDT - 7 weeks ago

Harrow: Exciting Times In Store

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 2:47 PM EDT - 7 weeks ago

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Harrow Announces Second-Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 7 weeks ago

Harrow Announces Second-Quarter 2025 Financial Results

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Aug 6, 2025, 7:00 AM EDT - 2 months ago

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Jul 29, 2025, 7:00 AM EDT - 2 months ago

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 2 months ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 2 months ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Jul 15, 2025, 10:38 AM EDT - 2 months ago

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Jul 11, 2025, 5:47 PM EDT - 3 months ago

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Harrow: Immense Upside Potential

Jul 9, 2025, 2:52 PM EDT - 3 months ago

Harrow: Immense Upside Potential

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 18, 2025, 7:00 AM EDT - 3 months ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

I Am Swimming In Dividends With +7% Yields

Jun 13, 2025, 8:30 AM EDT - 4 months ago

I Am Swimming In Dividends With +7% Yields

UMH

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Jun 9, 2025, 7:00 AM EDT - 4 months ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Harrow: Epic Growth & Operating Leverage On Full Display

May 28, 2025, 3:20 PM EDT - 4 months ago

Harrow: Epic Growth & Operating Leverage On Full Display

Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 5 months ago

Harrow to Present at Two Investor Conferences in May

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 10, 2025, 6:17 PM EDT - 5 months ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

Harrow Announces First-Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 5 months ago

Harrow Announces First-Quarter 2025 Financial Results

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

May 5, 2025, 7:00 AM EDT - 5 months ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 24, 2025, 10:00 AM EDT - 5 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Apr 10, 2025, 7:00 AM EDT - 6 months ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 29, 2025, 4:30 PM EDT - 6 months ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 2:00 PM EDT - 6 months ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Mar 28, 2025, 1:39 PM EDT - 6 months ago

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 4:01 PM EDT - 6 months ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 27, 2025, 10:45 AM EDT - 6 months ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Mar 24, 2025, 7:00 AM EDT - 6 months ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Mar 17, 2025, 4:01 PM EDT - 7 months ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Harrow Launches VEVYE® Access for All

Mar 17, 2025, 7:00 AM EDT - 7 months ago

Harrow Launches VEVYE® Access for All

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Mar 11, 2025, 7:00 AM EDT - 7 months ago

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Mar 3, 2025, 7:15 AM EST - 7 months ago

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Mar 1, 2025, 8:50 AM EST - 7 months ago

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Jan 27, 2025, 7:30 AM EST - 8 months ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

COR

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Jan 7, 2025, 7:00 AM EST - 9 months ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Those Derisked Baby Bonds Of Harrow, Inc.

Jan 3, 2025, 3:43 PM EST - 9 months ago

Those Derisked Baby Bonds Of Harrow, Inc.

Harrow: The Triesence Relaunch

Dec 14, 2024, 12:09 AM EST - 10 months ago

Harrow: The Triesence Relaunch

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Nov 21, 2024, 7:00 AM EST - 11 months ago

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Harrow Announces Participation in Upcoming Investor Conferences

Nov 15, 2024, 7:00 AM EST - 11 months ago

Harrow Announces Participation in Upcoming Investor Conferences

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 2:56 PM EST - 11 months ago

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Night_Owl_Biotech
Night_Owl_Biotech Oct. 4 at 10:21 PM
The attachment compares the projected revenue & EPS multiples of $LGND v. 3 peers $RPRX $XNCR $XOMA that also invest in biopharma royalties. LGND appears to be an amazing company with a great future. We are not bashing LGND. However, simple analytics suggest LGND, up ~80%+ since June 2025, is now over-priced primarily because they trade @ multiples 2X higher than these 3 peers. Of course we could be wrong. This is not investment advice. Shorting a stock like LGND is extremely risky because, in theory, losses are infinite. History suggests LGND might retract after reporting Q3 2025 earnings as valuation opportunity are reset (the $HROW phenomenon in May 2023...but HROW recovered & then some later). LGND also holds equity investments where valuation gains may not manifest in traditional revenues & earnings forecasts. Again, this is not investment advice. Comments? Pushback? Are these 3 not peers?
0 · Reply
Finnish_boy
Finnish_boy Oct. 4 at 9:37 PM
$HROW I will be quiet until next friday. Lets see if MVI posts BBG data. Buy all the bigger dips. Very tasty IPA ⬇️
0 · Reply
Finnish_boy
Finnish_boy Oct. 4 at 11:19 AM
$HROW
1 · Reply
Finnish_boy
Finnish_boy Oct. 4 at 9:38 AM
$HROW OSRX should have respected the rules. Think first before acting. Now the court did what they had to: https://youtube.com/shorts/7cuKeZMOCN4?si=jrtSEeRuo9yGcb8m
0 · Reply
Finnish_boy
Finnish_boy Oct. 4 at 8:52 AM
$HROW What you think will happen? OSRX will give up and pay what they can. Or they complain and delay the payments for 1-2 years and meanwhile they gather all the money to own pockets and find new jobs. OSRX will lose 100% sure anyways. What you think? Give up or delay?
2 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 8:30 AM
$HROW: Unusual Options Activity Alerted CALL flow observed 90x contracts at Strike price of $49 Exp on 11/21/2025 with Premium of $50K and showing NEUTRAL Sentiment
0 · Reply
MrMoneyBags4
MrMoneyBags4 Oct. 4 at 6:42 AM
$HROW Charts still look good. - Monthly: Structural uptrend intact. - Weekly: Still bullish — pullback within trend. - Daily: Short-term consolidation (typical after a run).
1 · Reply
Fullback
Fullback Oct. 3 at 10:47 PM
$HROW I didn't see this to just now, but maybe this might have been a driver for SP today? https://x.com/RevShark/status/1974117881563451702
2 · Reply
Finnish_boy
Finnish_boy Oct. 3 at 9:42 PM
$HROW https://www.vitallaw.com/news/trademark-s-d-cal-remittitur-granted-in-eye-medication-infringement-dispute/ipm0135d19d4ebb854eb38fd87fe0369f6e15?refURL=https%3A%2F%2Fwww.google.com%2F#.
1 · Reply
Finnish_boy
Finnish_boy Oct. 3 at 9:41 PM
$HROW
0 · Reply
holdor910
holdor910 Oct. 3 at 8:43 PM
$HROW There’s been a lot of recent discussion on Q3 earnings and today's price action. It's also important to keep perspective on where Harrow will be in a few years. We're talking about the potential of becoming a leading ophthalmic company on the scale of an Alcon or Allergan (20x–40x outcome). Execution is already in motion, with EPS forecasted to grow 100% YoY. $2 in 2026, $4 in 2027, $8 in 2028.
1 · Reply
Finnish_boy
Finnish_boy Oct. 3 at 7:12 PM
$HROW Calling Baum where we use that money "A California federal judge has rejected a motion for a new trial in a trademark case between eyedrop makers after a jury awarded one side $35 million, saying there was plenty of evidence to support a finding of infringement while reducing the damages award to about $11.2 million."
2 · Reply
SafeMargins
SafeMargins Oct. 3 at 7:05 PM
$HROW I just used that IQVIA Iheezo chart to compare the Q1 to Q2 growth to see how that lined up with reality . . and it did not do well. Using the 13 week moving average line there was a 20% increase last week of Q1 to Q2. and iheezo did 5.2M in Q1 and 18.3M in Q2. So I'm gonna say that the IQVIA iheezo data sucks too. also according to that chart Q4 and Q2 should have been very close, but Q4 did 22.8M, quite a bit more then Q2. So I am going to say that it's not very useful for forecasting the iheezo revenue.
2 · Reply
Finnish_boy
Finnish_boy Oct. 3 at 6:59 PM
$HROW Bradley is our man again? He likely buys the dip.
0 · Reply
Finnish_boy
Finnish_boy Oct. 3 at 6:08 PM
$HROW Whoever are selling, they likely want to tell us "have a good weekend" by forcing SP under $45. My October PT still $55, November $65, December $70 H1 next year $85, H2 $100.
1 · Reply
Finnish_boy
Finnish_boy Oct. 3 at 5:41 PM
$HROW
1 · Reply
Fullback
Fullback Oct. 3 at 5:17 PM
$HROW Already exceeded avg daily volume.
1 · Reply
highnihilism
highnihilism Oct. 3 at 4:51 PM
$SPGI S&P Global Trades: 240 | Total $: 777.7 K | 0.43 × 90-Day Avg $: 1.83 M | Call $: 526.3 K | Put $: 251.4 K | Single-Leg: 92% | Multi-Leg: 8% $GRRR Gorilla Tech Trades: 835 | Total $: 596.8 K | 0.43 × 90-Day Avg $: 1.39 M | Call $: 534.5 K | Put $: 62.3 K | Single-Leg: 89% | Multi-Leg: 11% $DNA Ginkgo Bioworks Holdings Trades: 321 | Total $: 556.2 K | 2.35 × 90-Day Avg $: 236.6 K | Call $: 532.1 K | Put $: 24.1 K | Single-Leg: 89% | Multi-Leg: 11% $HROW Harrow Trades: 204 | Total $: 599.4 K | 1.68 × 90-Day Avg $: 357.5 K | Call $: 531.7 K | Put $: 67.7 K | Single-Leg: 100% | Multi-Leg: 0%
0 · Reply
Finnish_boy
Finnish_boy Oct. 3 at 3:48 PM
$HROW I'm incredible stupid human. I bought extra shares of HROW between $35-44. I adjusted my target from $45 to $54-55. My plan was to sell HROW and then buy IREN under $50 and CIFR under $15. Both dipped -20% but now both skyrocketing. I should have reacted more fast and sell HROW at $50 and buy the dip on data center stocks. Next time i will react faster. But yea, dont sell any core position on HROW. I am talking about my extra shares and i ruined my "trading plan" already. I missed 25% gains. I hate trading. That's why i dont do that. I am always too greedy. Never play casinos, sport betting, or stock trading. you likely lose all money at the end. If you have limits and it's fun entertainment, then different thing.
3 · Reply
ACNY555
ACNY555 Oct. 3 at 2:14 PM
$HROW looking to add more to my position. What do the chart geeks think we support at?
1 · Reply
Fullback
Fullback Oct. 3 at 1:51 PM
$HROW Added today at $45.73 and $45.37 ~$3000.00 worth.
2 · Reply
Lufthana
Lufthana Oct. 3 at 1:50 PM
$HROW why stock down 5% on heavy volume? No news
1 · Reply